| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Foreign exchange (loss) gain | -12 | 21 | 4 | 5 |
| Total other income | 917 | 1,035 | 1,173 | 1,723 |
| Net loss | -7,742 | 2,523 | -24,526 | -19,717 |
| Unrealized gain on available-for-sale securities | 58 | -21 | -31 | 218 |
| Comprehensive loss | -7,684 | 2,502 | -24,557 | -19,499 |
| Basic (in shares) | 191,778,950 | 191,551,282 | 190,707,085 | 188,997,194 |
| Basic (in usd per share) | -0.04 | 0.01 | -0.13 | -0.1 |
| Diluted (in shares) | 191,778,950 | 192,399,733 | 190,707,085 | 188,997,194 |
| Diluted (in usd per share) | -0.04 | 0.01 | -0.13 | -0.1 |
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)